AstraZeneca: Just a bit of outsourcing

Did we say that? AstraZeneca is now denying any intention of outsourcing all its manufacturing, saying the EVP who'd called production "not a core activity" was misquoted. But, the company says, it will begin looking to contract manufacturers in India and China for some active ingredients in various meds.

-read this article in Pharmafocus 

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.